Antiviral drugs in the prophylaxis of HBV infection

Current Medicinal Chemistry

Volumn 19, Issue 35, 2012, Pages 5940-5946

  Masgala, A ^a   Nikolopoulos, G ^b   Tsiodras, S ^b,c   Bonovas, S ^b,d   Sitaras, N M ^d  

^a AGIA OLGA HOSPITAL   (Greece)

^b Hellenic Centre for Disease Control and Prevention   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Antiviral drugs; HBV infection; Immunosuppression; Nucleos(t)ide analogues; Prophylaxis

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALEMTUZUMAB; ANTHRACYCLINE; ANTIVIRUS AGENT; CORTICOSTEROID; CYTOVEN; ENTECAVIR; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; RITUXIMAB; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ARTICLE; DISEASE CARRIER; DRUG CYTOTOXICITY; DRUG SOLUBILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOCOMPROMISED PATIENT; INJECTION SITE PAIN; LIVER TRANSPLANTATION; MONOTHERAPY; REINFECTION; SOLID TUMOR; VIRUS REACTIVATION;

ANTIVIRAL AGENTS; HEMATOLOGIC NEOPLASMS; HEPATITIS B; HUMANS; IMMUNOSUPPRESSION; LIVER NEOPLASMS; LIVER TRANSPLANTATION; VIRUS ACTIVATION;

EID: 84871342322     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712804485980     Document Type: Article

References (140)

1. Ganem, D.; Prince, A. M. Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med., 2004, 350, 1118-1129.
2. Yeo, W.; Johnson, J. P. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology, 2006, 43, 209-220.
3. Chen, C. J.; Yang, H. L; Su, J.; Jen, C. L.; Lu, S. N.; Huang, G. T.; Hoeje, U. H. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 2006, 295, 65-73.
4. Luo, K. X.; Zhou F. Y.; Lu D. L.; Feng, X. R. Simple nucleos (t) ides as HBV prophylaxis regimen of post-transplantation: Six-year followed up. World J. Hepatol., 2010, 2, 447-450.
5. McGory, R. W.; Ishitani, M. B.; Oliveira, W. M.; Stevenson, W. C.; McGullouch, C. S.; Dickson, R. C.; Calwell, S. H.; Pruett, T. L. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplanation, 1995, 61, 1358-1364.
6. ten Kate, F. J. W.; Schalm, S. W.; Willemse, P. J. A.; Blok, A. P. R.; Heijtink, R. A.; Terpstra, O. T. Course of hepatitis B and D virus infection in auxillary liver grafts in hepatitis B positive patients. J. Hepatol., 1992, 14, 168-175.
7. Samuel, D.; Muller, R.; Alexander, G.; Fassati, L.; Ducot, B.; Benhamou, J. P.; Bismuth, H. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med., 1993, 329, 1842-1847.
8. Asmuth, D. M.; Nguyen, H. H.; Meilher, G. P.; Cohen, S. H.; Pollard, R. B. Treatments for Hepatitis B. Clin. Infect. Dis., 2004, 39, 1352-1362.
9. Samuel, D.; Bismuth, H.; Liver transplantation for hepatitis B. Gastroenterol. Clin. North Am., 1993, 22, 271-283.
10. Grazi, G. L.; Mazziotti, A.; Sama, C.; Jovine, E.; Stefanini, F.; Paladini, R.; Rossi, R.; Cavallari, A. Liver transplanation in HbsAg-positive HBV-DNA-negative cirrhotics: immunoprophylaxis and long-term outcome. Liver Transpl. Surg., 1996, 2, 418-425.
11. Samuel, D.; Bismuth, H.; Mathieu, D.; Arulanden, J. L.; Reynes, M.; Bennhamou, J. P.; Brechot, C.; Bismuth, H. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet, 1991, 37, 813-815.
12. Roche, B.; Samuel, D. Evolving strategies to prevent HBV recurrence. Liver Transpl., 2004, 10, 74-85.
13. Celis, E.; Abraham, K. G.; Miller, R. W. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology, 1987, 7, 763-769.
14. Rath, S.; Devey, M. E. IgG subclass composition of antibodies to HbsAg in circulating immune complexes from patients with hepatitis B virus infection. Clin. Exp. Immunol., 1988, 72, 164-167.
15. Konig, V.; Hopf, U.; Neuhaus, P.; Bauditz, J.; Schmidt, C.; Blumhardt, G.; Bechstein, W.; Neuhus, R.; Lobeck, H. Long-term follow up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplanation, 1994, 58, 553-559.
16. Shouval, D.; Samuel, D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology, 2000, 32, 1189-1195.
17. Roche, B.; Feray, C.; Gigou, M.; Roque-Afonso, A. M.; Arulnaden, J. L.; Delvart, V.; Dussaix, E.; Guertier, C.; Bismuth, H.; Samuel, D. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology, 2003, 38, 86-95.
18. Burbach, G. J.; Bienze, U.; Neuhaus, R.; Hopf, U.; Metzger, W. G.; Pratschke, J.; Neuhaus, P. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplanation, 1997, 63, 478-480.
19. Alonso, I.; Herreros de Tejada, A.; Moreno, J. M.; Rubio, E.; Lucena, J. L.; De la Revilla, J.; Sanchez Turrion, V.; Gomez, A.; Lopez, A.; Cuevas-Mons, V. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplanation: preliminary report. Transplant. Proc., 2003, 35, 1850-1851.
20. Yao, F. A.; Osorio, R. W.; Roberts, J. P.; Poordad, F. F.; Briceno, M. N.; Garcia-Kennedy, R.; Gish, R. R. Intramuscular hepatitis B immune blobulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl. Surg., 1999, 5, 491-496.
21. Yoshida, E. M.; Erb, S. R.; Partovi, N; Scudamore, C. H.; Churg, S. W.; Frighetto, L.; Eggen, H. J.; Steinbrecher, U. P. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin Liver Transpl. Surg., 1999, 5, 520-525.
22. Adler, R.; Safadi, R.; Caraco, Y.; Rowe, M.; Etzioni, A.; Ashur, Y; Shouval, D. Comparison of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology, 1999, 29, 1299-1305.
23. Scheiermann, N; Kuwert, E. K. Uptake and elimination of hepatitis B immunoglobulins after intramuscular application in man. Dev. Biol. Stand., 1983, 54, 347-355.
24. Wahl, M.; Hermodsson, S.; Kjellman, H.; Iwarson, S. Recovery and turnover rate of hepatitis B immunoglobulin in volunteers. Dev. Biol. Stand., 1983, 54, 341-345.
25. Nymann, T.; Shokoub-Amiri, M. H.; Vera, S. R.; Riely, C. A.; Alloway, R. R.; Gaber, A. O. Prevention of hepatitis B recurrence with indefinite hepatitis B immune globulin (HBIG) prophylaxis after liver transplantation. Clin. Transplant, 1996, 10, 663-667.
26. Lee, W. C.; Jeng, L. B.; Wang, C. C.; Chen, M. F.; Chien, R. N.; Chiu, C. T.; Ling, D. Y; Liaw, Y. F.; Chang, C. H. Long-term immunoprophylaxis for hepatitis B virus reinfection after liver transplantation. Transplant. Proc, 1996, 28, 1699-1700.
27. Bronger, M.; Elias, A.; Vitrano, L.; Jaulin, P. Collection of anti-HBs hyperimmune plasma: stimulation by Genhevac B in weakly immunized donors. Rev. Fr. Transfus. Hemobiol, 1992, 35, 325-334.
28. Oon, C. J.; Lim, G. K.; Ye, Z.; Goh, K. T.; Tan, K. L.; Yo, S. L.; Hopes, E.; Harrison, T. J.; Zuckerman, A. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine, 1995, 13, 699-702.
29. Trautwein, C; Schrem, H.; Tillmann, H. L.; Kubicka, S.; Walker, D.; Boker, K. H.; Maschek, H. J.; Pichlmayr, R.; Manns, M. P. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. Hepatology, 1996, 24, 482-488.
30. Carman, W. F.; Trauwein, C; van Deursen, F. J.; Colman, K.; Dornan, E.; Mclntyre, G.; Weters, J.; Klem, V.; Muller, R.; Thomas, H.; Manns, M. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology, 1996, 24, 489-493.
31. Sterneck, M.; Gunther, S.; Gerlach, J.; Naoumov, N. V.; Santantonio, T.; Fischer, L.; Rogiers, X.; Greten, H.; Williams, R.; Will, H. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. J. Hepatol, 1997, 26, 754-764.
32. Ghany, M. G.; Ayola, B.; Villamil, F. G.; Gish, R. G.; Roijter, S.; Vierling, J. M.; Lok, A. S. Hepatitis B virus mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology, 1998, 27, 213-222.
33. Terrault, N. A.; Zhou, S.; McCory, R. W.; Pruet, T. L.; Lake, J. R.; Roberts, J. P; Ascher, N. L.; Wright, T. L. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology, 1998, 28, 555-561.
34. Protzer-Knolle, U.; Naumann, U.; Bartenschlager, R.; Berg, T.; Hopf, U.; Meyer zum Buschenfelde, K. H.; Neuhaus, P.; Gerken, G.; Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology, 1998, 27, 254-263.
35. U. S. Department of Health and Human Services.. AIDS info. Lamivudine. http//www.aidsinfo.nih.gov (assessed April 12, 2012).
36. Lai, C. N.; Chien, R. N.; Leung, N. W.; Chang, T. T.; Guan, R.; Tai, D.; Ng, K. Y; Wu, PC; Dent, J. C.; Barber, J.; Stephenson, S.; Gray, D. F. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med., 1998, 61, 339-361.
37. Liaw YF. Results of lamivudine trials in Asia. J. Hepatol, 2003, S1, 111-115.
38. Bock, C. T.; Tillmann, H. L.; Torresi, J.; Klempnauer, J.; Locarnini, S.; Manns, M. P; Trautwein, C. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology, 2002, 122, 264-273.
39. Nath, D.; Kalis, A.; Nelson, S.; Payne, W.; Lake, J.; Humar, R. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy. Clin. Tranplant, 2006, 20, 206-210.
40. Castells, L.; Campos-Varela, I; Buti, M.; Esteban, R. Pharmacokinetics of intramuscular and intravenous HBIG: Which implications for practice? Dig. Liver Dis. Suppl, 2009, 3, 119-123.
41. Mutimer, D.; Pillay, D.; Shields, P.; Cane, P.; Ratcliffe, D.; Matin, B.; Buchan, S.; Boxall, L.; Donelli, K.; Shaw, J.; Hubscher, S.; Elias, E. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant patient. Gut, 2000, 46, 107-113.
42. Leung, N. W.; Lai, C. L.; Chang, T. T.; Guan, R.; Lee, CM.; Ng, K. Y; Lim, S. G.; Wu, PC; Dent, J. C.; Edmundson, S.; Condrreay, L. D.; Chien, R. N. Extended lamivudine treatment in patients with chronic hepatitis B enhance hepatitis Be antigen seroconversion rates: results after 3 years of therapy. Hepatology, 2001, 33, 1527-1532.
43. Woo, H. Y; Choi, J. Y; Jang, J. W.; You, C. R.; Bae, S. H.; Yoon, S. K.; Yaang, J. M.; Choi, S. W.; Han, N. I.; Kim, D. G. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J. Med. Virol., 2008, 80, 1891-1899.
44. Lee, H. W.; Suh, K. S.; Yi, N. J.; Yang, S. H.; Cho, E. H.; Cho, J. Y.; Kwon, C. H.; Cho, Y. B.; Lee, K. U. Preoperative lamvudine therapy in HBV DNA positive recipients: is it always necessary? Hepatogastroenterology, 2007, 54, 1783-1787.
45. Perrillo, R.; Hann, H. W.; Mutimer, D.; Willems, B.; Leung, N.; Lee, W. M.; Moorat, A.; Gardner, S.; Woessner, M.; Bourne, E.; Brosgart, C. L.; Schiff, E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterolog y, 2004, 126, 81-90.
46. Schiff, E.; Simsek, H.; Lee, W. M.; Chao, Y. C.; Sette, H.; Janssen, H. L.; Han, S. H.; Goodman, Z.; Yang, J.; Brett-Smith, H.; Tamez, R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am. J. Gastroenterol., 2008, 103, 2776-2783.
47. Honaker, M. R.; Shokouh-Amiri, M. H.; Vera, S. R.; Alloway, R. R.; Greval, H. P.; Hardinger, K. L.; Kizlisk A. T.; Baqous, T.; Trofe, J.; Stratta, R. J.; Egidi, M. F.; Gaber, A. O. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl. Infect. Dis., 2002, 4, 137-143.
48. Xunrong, L.; Yan, W. A.; Liang, R.; Lau, K. Hepatitis B virus reactivation after cytotoxic or immunosuppressive therapy-pathogenesis and management. Rev. Med. Virol., 2011, 11, 287-299.
49. Angus, P. W.; McGauchan, G. W.; Gane, E. J.; Crawford, D. H.; Harley, H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transplant., 2000, 6, 429-433.
50. Rao, W.; Wu, X.; Xiu, D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl. Int., 2009, 22, 387-394.
51. Katz, L. H.; Paul, M.; Guy, D. G.; Tur-Kaspa, R. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl. Infect. Dis., 2010, 12, 292-308.
52. Jiang, L.; Yan, L.; Li, B.; Wen, T.; Zhao, J.; Jiang, L.; Cheng, N.; Wei, Y.; Yang, J.; Xu, M.; Wang, W. Prophylaxis against hepatitis B recurrence posttransplanation using lamivudine and individualized low dose hepatitis B immunoglobulin. Am. J. Transplant., 2010, 10, 1861-1869.
53. Yoshida, H.; Kato, T.; Levi, D. M.; Regev, A.; Madariaga, J. R.; Nishida, S.; Martinez, E. J.; Schif, E. R.; Omata, M.; Tzakis, A. G. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin. Transplant., 2007, 21, 166-171.
54. Boni, C.; Bertoletti, A.; Penna, A.; Cavalli, A.; Pilli, M.; Urbani, S.; Sconamiglio, P.; Boehme, R.; Panebiaco, R.; Fiaccadori, F.; Ferrari, C. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J. Clin. Invest., 1998, 102, 968-975.
55. Lo, C. M.; Fung, J. T.; Lau, J. K.; Liu, C. L.; Cheung, S. T.; Lai, C. L.; Fan, S. T.; Wong, J. Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. Hepatology, 2003, 37, 36-43.
56. Lo, C. M.; Liu, C. L.; Chan, S. C.; Lau, G. K.; Fan, S. T. Failure of hepatitits B vaccination in patients receiving lamivudine after liver transplantation for chronic hepatitis. Br. J. Hepatol., 2005, 45, 283-287.
57. Angelico, M.; Di Paolo, D.; Trinito, O. M.; Petrolati, A.; Araco, A.; Zazza, S.; Lionetti, R.; Failure of reinforced triple course of hepatitis B vaccination in patients transplanted for HBV related cirrhosis. Hepatology, 2002, 35, 176-181.
58. Arbizu, A. E.; Marugan, B. R.; Nieto, O. E.; Alonso, C. E.; Gonzalez, M. G.; Garcia, J. M.; Vasquez-Garza, N. J.; Davila, M. P. Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: preliminary results. Transplantation Proc., 2003, 35, 1843-1849.
59. U. S. Department of Health and Human Services. AIDS info. Adefovir dipivoxil. http//www.aidsinfo.nih.gov (assessed April 12, 2012).
60. Chang, T.; Lai, C. Hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med., 2006, 355, 322-323.
61. Schildgen, O.; Sirma, H.; Funk, A. Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med., 2006, 354, 1807-1812.
62. Thio, C.; Locarnini, S. Treatment of HIV-HBV co-infection: clinical and virological issues. AIDS Rev., 2007, 9, 40-53.
63. Katayali, E.; Katayalcin, S.; Karaaslan H. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment. Antivir. Ther., 2007, 12, 761-768.
64. Marcellin, P.; Chang, T. T.; Lim, S. G.; Tong, M. J.; Sievert, W.; Shiffman, M. L.; Jeffers, I.; Goodman, Z.; Wulfsohn, M. S.; Xiong, S.; Fry, J.; Brosgart, C. L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med., 2003, 348, 808-816.
65. Xiong, X.; Flores, C.; Yang. H.; Toole, J. J.; Gibbs, C. S. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology, 1998, 28, 1669-1673.
66. Lo, C. M.; Liu, C. L.; Lau, G. K.; Chan, S. C.; Ng, I. O.; Fan, S. T. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transpl., 2005, 11, 807-813.
67. Wai, C. T.; Prabhakaran, K.; Wee, A.; Lee, Y. M.; Dan, Y. Y.; Sutedja, D. S.; Mak, K.; Isaac, J.; Lee, K. H.; Lee, H. L.; Da Costa, M.; Lim, S. G. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transplant. Proc., 2004, 36, 2313-2314.
68. Lo, C. M.; Cheung, S. T.; Ng, I. O.; Liu, C. L.; Lai C. L.; Fan, S. T. Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. Liver Transpl., 2004, 10, 557-563.
69. Akyildiz, M.; Karasu, Z.; Zeytunlu, M.; Aydin, U.; Ozacar, T.; Kilic, M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J. Gastroenterol. Hepatol., 2007, 22, 2130-2134.
70. Hwang, S.; Ahn, C. S.; Song, G. W.; Kim, K. H.; Moon, D. B.; Oh, H. B.; Lim, Y. S.; Lee, H. C.; Ha, T. Y.; Jung, D. H.; Chung, Y. H.; Lee, S. G. Posttransplantation prophylaxis with primary high dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on. Liver Transpl., 2011, 17, 456-465.
71. Marzano, A.; Lampetico, P.; Mazzaferro, V.; Carenzi, S.; Vigano, M.; Romito, R.; Pulvirenti, A.; Franchello, A.; Colombo, M.; Salizzoni, M.; Rizzetto, M. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl., 2005, 11, 532-538.
72. Yang, Y.; Zhang, O.; Cai, C. J.; Lu, M. Q.; Li, X.; Jiang, H.; Xu, C.; Li, H.; Wang, G. S.; Yi, S. H.; Zhang, J.; Zhang, J. F.; Yi, H. M.; Zhang, Y. C.; Chen, G. H. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. Clin. Med. J., 2007, 120, 1400-1403.
73. Schiff, E.; Lai, C.; Hadziyannis, S.; Neuhaus, P.; Terrault, N.; Colombo, M.; Tillmann, H.; Samuel, D.; Zeuzem, S.; Villleneuve, J. P.; Arterburn, S.; Borroto-Esoda, K.; Brosgart, C.; Chuck, S. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl., 2007, 13, 349-360.
74. U. S. Department of Health and Human Services. AIDS info. Entecavir. http//www.aidsinfo.nih.gov (assessed April 12, 2012).
75. Tenney, D. J.; Levine, S. M.; Rose, R. E.; Walsh, A. W.; Weinheimer, S. P.; Discotto, L.; Plym, M.; Pokomowski, K.; Yu, C.; Angus, P.; Ayres, A.; Bartholomeusz, A.; Sivert, W.; Thomson, G.; Warner, N.; Locarnini, S.; Colonno, R. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitution in virus already resistant to Lamivudine. Antimicrob. Agents Chemother., 2004, 48, 3498-3507.
76. Luo, K. X.; Zhou, F. Y.; Liu, D. L.; Feng, X. R. Simple nucleos (t) ides as HBV prophylaxis regime of post-liver transplantation: Six-year followed up. World J. Hepatol., 2010, 2, 447-450.
77. Fung, J.; Cheung, C.; Chan, S.; Yuen, M.; Chok, K.; Sharr, W.; Dai, W. C.; Chan, A.; Cheung, T.; Tsang, S.; Lam, B.; Lai, C.; Lo C. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology, 2011, [Epub ahead of print].
78. Ueda, Y.; Marusawa, H.; Egawa, H.; Okamoto, S.; Ogura, Y.; Oike, F.; Nishijima, N.; Uemoto, S.; Chiba, T. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir. Ther., 2011, 16, 479-487.
79. Xi, Z. F.; Xia, Q.; Zhang, J.; Chen, X. S.; Han, L. Z.; Wang, X.; Shen, C. H.; Luo, Y.; Xin, T. Y.; Wang, S. Y.; Qiu De, K. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J. Dig. Dis., 2009, 10, 321-327.
80. Himenez-Perez, M.; Saez-Gomez, A. B.; Mongil Poce, L.; Lozano-Rey, J. M.; de la Cruz-Lombardo, J.; Rodrigo-Lopez, J. M. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant. Proc., 2010, 42, 3167-3168.
81. U. S. Department of Health and Human Services. AIDS info. Tenofovir disoproxil fumarate. http//www.aidsinfo.nih.gov (assessed April 12, 2012).
82. Lok, S. F. A.; McMahon, J. B. Chronic hepatitis B: Update 2009. Hepatology, 2009, 50, 661-697.
83. Drugbank.com. Tenofovir (DB00300). http://www.drugbank.com (accessed October 20, 2011).
84. Sheldon, J.; Camino, N.; Rodés, B.; Bartholomeusz, A.; Kuiper, M.; Tacke, F.; Nùñez, M.; Mauss, S.; Lutz, T.; Klausen, G.; Locarnini, S.; Soriano, V. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther., 2005, 10, 727-734.
85. Taltavull, T. C.; Chahri, N.; Verdura, B.; Gornals, J.; Lopez, C.; Casanova, A.; Canas, C.; Figueras, J.; Casais, L. A. Successful treatment with tenofovir in a child C cirrhotic patient with lamivudine-resistant hepatitis B virus awaiting liver transplantation. Post-transplant results. Transpl. Int., 2005, 18, 879-883.
86. Drugbank.com. Famciclovir (DB00426). http://www.drugbank.com (accessed October 20, 2011).
87. Singh, N.; Gayowski, T.; Wannstedt, O. F.; Wagener, M. M.; Marino, I. R. Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplanation, 1997, 63, 1415-1419.
88. Seehofer, D.; Rayes, N.; Naumann, U.; Neuhaus, R.; Muller A. R.; Tullius, S. G.; Berg, T.; Steinmuller, T.; Bechstein, W. O.; Neuhaus, P. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplanation, 2001, 72, 1381-1385.
89. Haller, G.; Bechstein, W.; Neuhaus, R.; Raakow, R.; Berg, T.; Hopf, U.; Neuhaus, P. Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation. Transpl. Int., 1996, 9(Suppl. 1), 210-212.
90. Kruger, M.; Tillman, H. L.; Trautwein, C.; Bode, U.; Oldhafer, K.; Maschek, H.; Boker, K. H.; Broelsch, C. E.; Pichmayr, R.; Manns, M. P. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study. Liver Transpl. Surg., 1996, 2, 253-262.
91. Rayes, N.; Seehofer, D.; Bechstein, W. O.; Muller, A. R.; Berg, T.; Neuhaus, R.; Neuhaus, P. Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation. Clin. Tranplant., 1999, 13, 447-452.
92. Manns, M. P.; Neuhaus, P.; Atkinson, G. F.; Griffin, K. E.; Barnass, S.; Vollmar, J.; Yeang, Y.; Young, C. L. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study. Transpl. Infect. Dis., 2001, 3, 16-23.
93. Borenguer, M.; Prieto, M.; Rayon, M.; Bustamante, M.; Carrasco, D.; Moya, A.; Pastor, M. A.; Gobernato, M.; Mir, J.; Berenguer, J. Famciclovir treatment in transplant recipients with HBV-related disease: disappointing results. Am. J. Gastroenterol., 2001, 96, 526-533.
94. Rayes, N.; Seehofer, D.; Hopf, U.; Neuhaus, R.; Naumann, U.; Bechstein, W. O.; Neuhaus, P. Comparison of famciclovir and lamivudine in the long term treatment of hepatitis B infection after liver transplantation. Transplantation, 2001, 71, 96-101.
95. Boker, K. H.; Ringe, B.; Kruger, M.; Pichmayr, R.; Manns, M. P. Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation, 1994, 57, 1706-1708.
96. Tillmann, H. L.; Trautwein, C.; Bock, T.; Boker, K. H.; Jackel, E.; Glowienka, M.; Oldhafer, K.; Bruns, I.; Gauthier, J.; Condreay, L. D.; Raab, H. R.; Manns, M. P. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIG immunoglobulin after liver transplantation. Hepatology, 1999, 30, 244-256.
97. Zheng, S. S.; Wu, J.; Liang, T. B.; Wang, W. L.; Huang, D. S.; Xu, X. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Transplantation, 2002, 3, 327-329.
98. U. S. Department of Health and Human Services. AIDS info. Ganciclovir. http//www.aidsinfo.nih.gov (assessed April 12, 2012).
99. Jurim, O.; Martin, P.; Winston, D. J.; Shackleton, C.; Holt, C.; Feller, J.; Csete, M.; Shaked, A.; Imagawa, D.; Olthoff, K.; Lau, J. Y.; Busutti, R. W. Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection. Liver Transpl. Surg., 1996, 295, 370-374
100. Gish, R. G.; Lau, J. Y.; Brooks, L.; Fang, J. W.; Steady, S. L.; Imperial, J. C.; Garcia-Kennedy, R.; Esquivel, C. O.; Keefe, E. B. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology, 1996, 23, 1-7.
101. Roche, B.; Samuel, D.; Gigou, M.; Feray, C.; Virot, V.; Majno, P.; Serraf, L.; David, M. F.; Dusseaix, E.; Reynes, M.; Bismuth, H. Long-term ganciclovir therapy for hepatitis B virus infection after liver transplantation. J. Hepatol., 1999, 31, 584-592.
102. Marzano, A.; Debernadi-Venon, W.; Smedile, A.; Brunetto, M. R.; Torrani Cerenzia, M. R.; Actis, G. C.; Zamboni, F.; Ghisetti, V.; Piantino, P.; David, E.; Salizzoni, M.; Rizetto, M. Recurrence of hepatitis B in liver transplant treated with antiviral therapy. Ital. J. Gastroenterol. Hepatol., 1998, 30, 77-81.
103. McCaughan, G.; Angus, P.; Bowden, S.; Shaw, T.; Breschkin, A.; Sheil, R.; Locarnini, S. Retransplantation for precore mutant-related chronic hepatitis B infection: prolonged survival in a patient receiving sequential ganciclovir/famciclovir therapy. Liver Transpl. Surg., 1996, 2, 472-474.
104. Angus, P.; Richards, M.; Bowden, S.; Ireton, J.; Sinclair, R.; Jones, R.; Locarnini, S. Combination antiviral therapy controls severe post-liver transplant recurrence of hepatitis B virus infection. J. Gastroenterol. Hepatol., 1993, 8, 353-357.
105. Singh, N.; Gayowski, T. Lack of sustained efficacy of combination ganciclovir and foscarnet for hepatitis B virus recurrence after liver transplantation. Transplantation, 1995, 59, 1629-1630.
106. Yeo, W.; Lam, K. C.; Zee, B.; Chan, P. S.; Mo, F. K.; Ho, W. M.; Wong, W. L.; Leung, T. W.; Chan, A. T.; Ma, B.; Mok, T. S.; Johnson, P. J. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann. Oncol., 2004, 15, 1661-1666.
107. Lok, A. S. F.; Liang, R. H.; Chiu, E. K. W.; Wong, K. L.; Chan, T. K.; Todd, D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology, 1991, 100, 182-188.
108. Yeo, W.; Chan, P. K.; Hui, P.; Ho, W. M.; Lam, K. C.; Kwan, W. H.; Zhong, S.; Johnson, P. J. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J. Med. Virol., 2003, 70, 553-561.
109. Cazelitz, M.; Link, H.; Hein, R.; Maschek, H.; Boker, K.; Poliwoda, H.; Manns, M. P. Hepatitis B associated liver failure following bone marrow transplantation. J. Hepatol., 1997, 27, 572-577.
110. Lau, G. K. K.; Lee, C. K.; Liang, R. Hepatitis B virus infection and allogeneic bone marrow transplantation. Crit. Rev. Oncol. Hematol., 1999, 31, 71-76.
111. Liang, R.; Lau, G. K. K.; Kwong, Y. L.; Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J. Clin. Oncol., 1999, 17, 394-398.
112. Yeo, W.; Chan, P. K.; Zhong, S.; Ho, W. M.; Steinberg, J. L.; Tam, J. S.; Hui, P.; Leung, N. W.; Zee, B.; Johnson, P. J. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J. Med. Viro l., 2000, 62, 299-207.
113. Cheng, A. L.; Hsiung, C. A.; Su, I. J.; Chen, P. J.; Chang, M. C.; Tsao, C. J.; Kao, W. Y.; Uen, W. C.; Hsu, C. H.; Tien, H. F.; Chao, T. Y.; Chen, L. T.; Whang-Peng, J. Steroid-free chemotherapy decreases risk of hepatitis B virus reactivation in HBV-carriers with lymphoma. Hepatology, 2003, 37, 1320-1328.
114. Yeo, W.; Zee, B.; Zhong, S.; Chan, P. K.; Wong, W. L.; Ho, W. M.; Lam, K. C.; Johnson, P. J. Comprehensive analysis of risk factors associating with hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. Br. J. Cancer, 2004, 90, 1306-1311.
115. Czuczman, M. S.; Grillo-Lopez, A. J.; White, C. A.; Saleh, M.; Gordon, L.; Lo Buglio, A. F.; Jonas, C.; Klippenstein, D.; Dallaire, B.; Varns, C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J. Clin. Oncol., 1999, 17, 268-276.
116. Skrabs, C.; Muller, C.; Agis, H.; Mannhalter, C.; Jager, U. Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia, 2002, 16, 1884-1886.
117. Lee, G. W.; Ryu, M. H.; Lee, J. L.; Oh, S.; Kim, E.; Lee, J. H.; Kim, S. B.; Kim, S. W.; Suh, C.; Lee, K. H.; Kim, W. K.; Lee, J. S.; Kang, Y. K. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBsAg)-positive patients with non-hodgkin's lymphoma who receive cytotoxic chemotherapy. J. Korean Med. Sci., 2003, 18, 849-854.
118. Idilman, R.; Arat, M.; Soydan, E.; Toruner, M.; Soykan, I.; Akbulut, H.; Arslan, O.; Ozcan, M.; Turkyilmaz, A. R.; Bozdayi, M.; Karayalcin, S.; Van Thiel, D. H.; Ozden, A.; Beksac, M.; Akan, H. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J. Viral Hepat., 2004, 11, 141-147.
119. Rossi, G.; Pelizzari, A.; Motta, M.; Puoti, M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br. J. Haematol., 2001, 115, 58-62.
120. Shibolet, O.; Ilan, Y.; Gills, S.; Hubert, A.; Shouval, D.; Safadi, R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers with lymphoid malignancies treated with chemotherapy. Blood, 2002, 100, 391-396.
121. Saab, S.; Dong, M. H.; Joseph, A. T.; Tong, J. M. Hepatitis B prophylaxis in patients undergoing chemotherapy for lymphoma: a decision analysis model. Hepatology, 2007, 46, 1049-1056.
122. Lau, K. K. G.; Yiu, H. Y. H.; Fong, Y. T. D.; Cheng, H. C.; Au, W. Y.; Lai, S. F. L.; Cheung, M.; Zhang, H. Y.; Lie, A.; Ngan, R.; Liang, R. Early is superior to deffered preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology, 2003, 25, 1742-1749.
123. Li, Y. H.; He, Y. F.; Jiang, W. Q.; Wang, F. H.; Lin, X. B.; Zhang, L.; Xia, Z. J.; Sun, X. F.; Huang, H. Q.; Lin, T. U.; He, Y. J.; Guan, Z. Z.; Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer, 2006, 106, 1320-1325.
124. Leaw, S. J.; Yen, C. J.; Huang, W. T.; Chen, T. Y.; Su, W. C.; Tsao, C. J. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann. Hematol., 2004, 83, 270-275.
125. Dai, M. S.; Wu, P. F.; Shyo, R. Y.; Lu, J. J.; Chao, T. Y. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver International., 2004, 24, 540-546.
126. Yeo, W.; Hui, P. E.; Chan T. C. A.; Ho, M. W.; Lam, C. K.; Chan, S. K. P.; Mok, S. K. T.; Lee, J. J.; Mo, F. K. F.; Johnson, J. P. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am. J. Clin. Oncol., 2005, 28, 379-364.
127. Huang, H.; Cai, Q.; Lin, T.; Lin, X.; Liu, Y.; Gao, Y.; Peng, R. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience. Expert Opin. Pharmacother., 2009, 10, 2399-2406.
128. Shitrit, B. G. A.; Kramer, R. M.; Bakal, I.; Morali, G.; Ari, B. Z.; Shidrit, D. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann. Thorac. Surg., 2006, 81, 1851-1852.
129. Murakami, R.; Amada, N.; Sato, T.; Ori, T.; Kikuchi, H.; Haga, I.; Ohashi, Y.; Okazaki, H. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience. Clin. Transplant., 2006, 20, 351-358.
130. Tsai, F. C.; Hsieh, S. C.; Chen, D. S.; Shen, J. C.; Chen, D. S. Reactivation of hepatitis B virus in rheumatologic patients receiving immunosuppressive agents. Dig. Dis. Sci., 2006, 51, 1627-1632.
131. Esteve, M.; Saro, C.; Gonzolez-Huix, F.; Suarez, F.; Forne, M.; Vive, M. J. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut, 2004, 53, 1363-1365.
132. Fouillard, I.; Serfaty, I.; Gozlan, I. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant., 2006, 37, 625-626.
133. Cortelezzi, A.; Vigano, M.; Zilioli, V. R.; Fantini, N. N.; Pasquini, C. M.; Colombo, M.; Lampertico, P. Adefovir added to lamivudine for hepatitis recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. J. Clin. Virol., 2006, 35, 467-469.
134. Henkes, M.; Martin, S.; Einsele, H.; Aulitzky, WE. Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation. Ann. Hematol., 2002, 81, 343-346.
135. Lau, G. K.; Liang, R.; Wu, P. C.; Lee, C. K.; Lim, W. L.; Au, W. Y. Use of famciclovir to prevent HBV reactivation in HbsAg-positive recipients after allogeneic bone marrow transplantation. J. Hepatol., 1998, 28, 359-368.
136. Wedemeyer, H.; Boker, K. H.; Pethig, K.; Petzold, D. R.; Flemming, P.; Tillmann, H. L.; Vollmar, J.; Basturk, M.; Golmann, E.; Griffin, K. E.; Haverich, A.; Manns, M. P. Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective study. Transplanation, 1999, 68, 1503-1511.
137. Tang, S.; Ho, S. K.; Moniri, K.; Lai, K. N.; Chan, T. M. Efficacy of famciclovir in the treatment of lamivudine resistance related to an atypical hepatitis B virus mutant. Transplantation, 2002, 73, 148-151.
138. Meisel, H.; Preikschat, P.; Reinke, P.; Hocher, B.; Budde, K.; Bechstein, W.; Neuhaus, P.; Kruger, D. H.; Neumayer, H. H. Disappearance of hepatitis B virus core delation mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine. Transpl. Int., 1999, 12, 283-287.
139. Mertens, T.; Kock, J.; Hampl, W.; Schlicht, H. J.; Tillmann, H. L.; Oldhafer, K. J.; Manns, M.; Arnold, R. Reactivated fulminant hepatitis B virus replication after bone marrow transplantation: clinical course and possible treatment with ganciclovir. J. Hepatol., 1996, 25, 968-971.
140. Anand, B. S.; Yoffe, B.; Young, J. B. Ganciclovir treatment of active hepatitis B virus infection in a heart transplant patient. J. Clin. Gastroenterol., 1996, 22, 144-146.